Picture of CRISM Therapeutics logo

CRTX CRISM Therapeutics News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Amur Minerals Corp - Press Speculation & Share Price Movement

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220125:nRSY5693Za&default-theme=true

RNS Number : 5693Z  Amur Minerals Corporation  25 January 2022

 

 

 

25 January 2022

 

AMUR MINERALS CORPORATION

 

("Amur" or the "Company")

 

(AIM: AMC)

 

Response to Press Speculation and Share Price Movement

 

 

Amur Minerals Corporation, a nickel-copper sulphide mineral exploration and
resource development company which possesses a wholly owned nickel sulphide
asset located in the far east of Russia, notes the recent share price movement
and press speculation that a potentially interested party has valued the
Company at an indicative price of up to £100 million. The Company confirms
that it is in discussions with a potential purchaser to sell its wholly owned
subsidiary, Irosta Trading Limited, for approximately the indicated price.
 Irostra Trading Limited owns the Kun-Manie Project.

Such a disposal would constitute a fundamental change of business under AIM
Rule 15 and therefore be subject to shareholder approval. There can be no
certainty that any agreement will be reached in respect of the proposed
disposal, nor as to the terms of the proposed disposal. A further announcement
will be made in due course.

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.

 

Enquiries:

 

 Company               Nomad and Broker                   Public Relations

 Amur Minerals Corp.   S.P. Angel Corporate Finance LLP   Blytheweigh
 Robin Young CEO       Richard Morrison                   Megan Ray

                       Adam Cowl                          Tim Blythe
 +7(4212)755615        +44(0)20 3470 0470                 +44 (0) 20 7138 3203

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  SPCPPUBGGUPPGGA

Recent news on CRISM Therapeutics

See all news